Akèy › Myelom Miltip › North Carolina › Durham
Etid klinik pou Myelom Miltip nan Durham, NC
37 etid pou Myelom Miltip ap chèche patisipan nan sit nan ak bò kote Durham (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Ap rekriteFaz 3
- Research Site, Chapel Hill · 10 mi lwen
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 3
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Ap rekriteFaz 2
- Duke University Medical Center, Durham
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · 10 mi lwen
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Ap rekriteFaz 3
- Durham VAMC, Durham
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Ap rekriteFaz 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · 10 mi lwen
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Ap rekriteFaz 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Ap rekriteFaz 3
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 2
- University of North Carolina Medical Center, Chapel Hill · 10 mi lwen
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Ap rekriteFaz 1/2
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · 10 mi lwen
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Ap rekriteFaz 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 13 mi lwen
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Ap rekriteFaz 1/2
- GSK Investigational Site, Chapel Hill · 10 mi lwen
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Ap rekriteFaz 1
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Ap rekriteFaz 1/2
- Research Site, Durham
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Ap rekriteFaz 3
- Research Site, Durham
- Research Site, Chapel Hill · 10 mi lwen
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Ap rekrite
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · 10 mi lwen
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Ap rekriteFaz 1
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Ap rekriteFaz 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · 10 mi lwen
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Ap rekriteFaz 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · 10 mi lwen
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Ap rekriteFaz 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1
- University of North Carolina /ID# 251203, Chapel Hill · 10 mi lwen
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Ap rekriteFaz 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi lwen
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Ap rekriteFaz 2
- University of North Carolina (Data Collection Only), Chapel Hill · 10 mi lwen
Registry of Older Patients With Cancer
Ap rekriteEtid obsèvasyon
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi lwen
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Ap rekriteFaz 3
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Ap rekriteFaz 2
- University of North Carolina, Chapel Hill · 10 mi lwen
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
Ap rekriteFaz 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Ap rekriteFaz 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · 10 mi lwen
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Ap rekriteFaz 1/2
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · 13 mi lwen
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Ap rekriteFaz 1
- University of North Carolina, Chapel Hill · 10 mi lwen
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Ap rekriteFaz 1
- University of North Carolina, Chapel Hill · 10 mi lwen
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Ap rekriteFaz 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · 10 mi lwen
Registry for Adults With Plasma Cell Disorders (PCD's)
Ap rekriteEtid obsèvasyon
- North Carolina Cancer Hospital, Chapel Hill · 10 mi lwen
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Ap rekriteEtid obsèvasyon
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi lwen
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Ap rekriteFaz 1
- Duke University Health System (DUHS), Durham
Etid Myelom Miltip nan lòt vil
- New York City, NY60 etid
- Boston, MA42 etid
- Atlanta, GA41 etid
- Houston, TX38 etid
- Nashville, TN32 etid
- Denver, CO27 etid
- Rochester, MN24 etid
- St. Louis, MO24 etid
- Columbus, OH24 etid
- Baldwin Park, CA23 etid
- Chicago, IL22 etid
- Seattle, WA22 etid
Lòt etid nan Durham
- Kansè nan tete63 etid
- Kansè (tout kalite)58 etid
- Kansè Poumon ki pa ti selil39 etid
- Kansè Metastatik33 etid
- Leksemi mieloïd egi33 etid
- Kansè poumon32 etid
- Kansè pwostat32 etid
- Kansè kolorektal28 etid
- Lukemi lenfositè kwonik27 etid
- Kansè ovè27 etid
- Ensifizyans kadyak26 etid
- Kansè pankreyas24 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.